EC authorises Celltrion’s Avtozma for multiple indications
Celltrion has secured marketing authorisation from the EC for Avtozma, a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab).
Celltrion has secured marketing authorisation from the EC for Avtozma, a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab).
What's Your Reaction?
